BDR Pharma seeks licence to sell version of Bristol-Myers Squibb cancer drug

.Mumbai: India’s BDR Pharmaceuticals International Pvt. Ltd has applied to the Indian patents office, seeking permission to sell a generic version of Bristol-Myers Squibb Co.’s cancer drug, dasatinib, through a so-called compulsory licence mechanism, a BDR executive said on Monday.

Under a global Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, countries can issue compulsory licences for certain drugs that are deemed unaffordable to a large section of their populations.
Early this month, Bayer AG lost an appeal challenging the first-ever compulsory licence issued by India which allowed Natco Pharma to sell a version of the German drugmaker’s cancer treatment Nexavar.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s